DOCSLIB.ORG

List of New Drugs Approved in India from 1961 to 1970

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of New Drugs Approved in India from 1961 to 1970 LIST OF NEW DRUGS APPROVED IN INDIA FROM 1961 TO 1970 S.No Name of Drug Pharmacological action/ Date of Indication Approval 1 Ephedrine Resonate 50mg Same as ephedrine, longer January-1961 Tablet duration of action. 2 Vasolastine Ampoule (2ml) Enzyme complexes exert a January-1961 normalising influence on the deamination of amino acids and on lipid metabolism. 3 Methychlothiazide 2.5mg/5mg Oral diuretic agent. Longest February-1961 Tablet duration: more sodium excretion less potassium loss. 4 O-Ethoxybenzamide Analgesic, Antiphlogistic, & February-1961 200mg/500mg Dragees Antipyretic. 5 P-Piperidinoethoxy-O- Antispasmodic and Analgesic. February-1961 Carbomethoxy Benzophenone Hydrochloride, 5mg/10mg Injection, Tablet & Suppository 6 Methocarbamol 1gm/1.5gm Skeletal muscle relaxant. February-1961 I.V Injection & Tablet 7 Benziquinone Guanyl Powerful oral and pharyngeal March-1961 Hydrazone Thiosemicarbazone disinfectant. (Ambazone) 10mg Troches 8 Metronidazole 250mg Oral Treatment of trichomonal March-1961 Tablet & 500mg Vaginal infestations. Tablet 9 Spiranolactone 100mg Tablet Promotes diuresis in patients March-1961 with oedema or ascites, resistant or partly resistant to conventional diuretics. 10 Triethanalamine Trinitrate Treatment of Angina pectoris. March-1961 Bisphosphate 8mg/16mg It is a vasodilator like glyceryl Tablets trinitrate. 11 Paromomycin 150mg Capsule Antibiotic for amoebiasis. March-1961 12 Xylometazoline Nasal drops Nasal decongestant. March-1961 (0.05% & 0.11% ) solution 13 Methdilazine 8mg Tablet & New long acting March-1961 Syrup Antihistaminic. 14 Isoxsuprine 10mg Tablet & Peripheral vasodilator. March-1961 Ampoule 15 Chlorthalidone 100/200mg A long acting oral diuretic. March-1961 Tablet 16 Mepenzolate methylbromite Anticholinergic. March-1961 25mg Tablet 17 Pipenzolate methylbromide Anticholinergic. March-1961 5mg Tablet 18 Piperidolate hydrochloride Anticholinergic. March-1961 50mg Capsule 19 Isopropamide iodide 5/10mg Anticholinergic. March-1961 Tablet 20 Oxymetholone 5mg Tablet Anabolic agent March-1961 21 Guanethidine (as sulphate) Antihypertensive April-1961 10/25mg Tablet 22 Methaqualone hydrochloride A new non-barbiturate April-1961 150mg Tablet Hypnotic. 23 Chlophedianol hydrochloride Anti-tussive April-1961 5% drops 24 N-Acetyl-Sulphamethoxy Long acting sulpha drug April-1961 Pyridiazine (Pediatric similar to Lederkyn. It is suspension) tasteless and more acceptable to children. 25 Fibrinolysin (human) 50000 & To promote the dissolution of April-1961 100000 units intravenous thrombi. 26 Chloramphenicol Palmitoyl For pediatric use. May-1961 Glycolate Suspension 27 Oxyphencyclamine Hcl. 10mg Powerful anticholinergic agent. May-1961 Tablet 28 Fluphenazene 0.5mg Tablet Anxiety & Tension only. May-1961 29 Norethindrone acetate 5mg Twice as potent as the parent June-1961 Tablet drug. 30 Hydroxycobalamine Injection Same as Vitamin B12. July-1961 31 Protokylol Hydrochloride Bronchodilator, antiasthmatic. July-1961 Injection (0.5mg) & Tablet (2mg) 32 Sodium-Iron Edetate 55mg Iron chelate-EDTA August-1961 Syrup 33 Betamethasone 0.5mg Tablet A corticosteroid. August-1961 34 Dexamethasone Trimethyl New salt for topical August-1961 Acetate Ointment (Ophth.) formulation. 35 Metformin Hcl. (0.5g) Tablet Oral hypoglycemic agent. September-1961 36 Chlorprothixene 50mg Tablet Anti depressant. September-1961 & 50mg Vial 37 Pipazethate 20mg Dragee & Anti-tussive September-1961 40mg/ml Drops 38 Pivazide 50mg Tablet Cardiac drug-reduces intensity September-1961 & frequency of anginal attacks. 39 Diphenhydramine (as methyl Anti-histaminic. September-1961 sulpho methylate / methyl sulphate) 60mg Tablet & 480mg/100ml Syrup 40 Edrophonium Chloride (10mg Cholinergic & curare October-1961 in 1cc) Ampoule antagonist. 41 Oxyphenbutazone 0.1gm Anti-inflammatory, antipyretic. November-1961 Tablet 42 2-Thymyloxy Methyl Vasoconstrictor. November-1961 Glyoxalidine Hcl. (0.05%) Nasal drops 43 Phenelzine Dihydrogen Anti-depressant. November-1961 Sulphate Tablet 44 Hamycin Vaginal Tablet & Antifungal antibiotic. November-1961 Suspension 45 Dequalinium Acetate Bacteriostatic. November-1961 46 Ethosuximide Tablet (250mg) Anticonvulsant for petitmal December- 1961 & Syrup (250mg/5ml) epilepsy. 47 Pimaricin 50mg Vaginal Tablet Anti fungal antibiotic for December- 1961 "Streptomyces natalensis". 48 Kanamycin Sulphate Vials of Antibiotic for cases resistant to December- 1961 2cc (0.5gm) other antibiotic, urinary tracks staphylococcus infections. 49 Prothipendyl Hydrochloride Psycho sedative & January-1962 20mg Dragee Tranquiliser-relaxes the autonomous system. 50 Ethionamide 250mg Tablet Anti-Tuberculosis drug, in February-1962 cases resistant to other drugs. 51 Nealbarbitone 60mg/200mg Barbiturates with more February-1962 Tablet sedative, less hypnotic effect. 52 Cyclopenthiazide 0.5mg Tablet Non-mercurial oral diuretic & February-1962 hypotensive. 53 Polythiazide 2mg Tablet Non-mercurial oral diuretic & February-1962 antihypertensive. 54 Trypsin-Kallikrein Inactivator Inactivates trypsin & February-1962 (5000 k.i.u) Ampoule Kallikrein-indicated in pancreatitis. 55 Sulpha-dimethyl Oxazole Intermediate acting sulpha March-1962 (Sulfamoxole) 0.5gm Tablet drug. 56 Ferrous Ethylene Diamine Oral iron compound (chelate March-1962 Tetra Acetate Trihydrate, 25mg form). & 50mg Drops 57 Bismuth Aluminate Tablet New bismuth salt (antacid). April-1962 58 Hexadimethrine Bromide Heparin antagonist. April-1962 (1.33mg for 100USP units of Heparin) 10mg/ml & 10ml Vials 59 Sorbide Nitrate 10mg Tablet Coronary vasodilator. April-1962 60 Cyproheptadine Hcl. (4mg) Anti-histaminic, anti-serotonin. April-1962 Tablet & (2mg/ml) Syrup 61 Pamabrom 50mg Tablet Diuretic. April-1962 62 Dexamethasone Sodium Corticosteroid, anti- April-1962 Metasulphobenzoate Injection inflammatory. 63 N-N-decamethylene-N-N- Anti-bacterial. May-1962 decamethylene-bis-amino quinaldine (Salvizol), 0.25mg Loz. & 0.4% Oint. 64 Iron-Sorbitol Citric Acid Haematinic-Parentral iron May-1962 Complex 2ml Injection (Colloidal iron complex). 65 Nandrolone Decanoate Anabolic effect, depot effect. May-1962 Injection 66 Clidinium Bromide 2.5mg/5mg Anti-cholinergic. May-1962 Tablet 67 Propyl Docetrizoate (75% w/v) Contrast medium in May-1962 20ml bronchography 68 Ethylestrenol 2mg Tablet Anabolic agent (oral). June-1962 69 Methenolone 1mg/5mg Tablet Anabolic agent June-1962 & Injection 70 Colistin 1.5MU/0.25MU Anabolic. June-1962 Tablet & 1MU Vial 71 Bisacodyl Tablet & Laxative. June-1962 Suppository 72 Isocarboxacid 10mg Tablet Anti-depressant. July-1962 73 Amitriptyline Hydrochloride Anti-depressant. August-1962 10/25mg Tablet & 10mg/cc 74 Chlormezanone 100mg Tablet Muscle relaxant & tranquiliser. August-1962 75 Isopregnenone Oral progesterone agent. August-1962 (Dydrogestrone) 5mg Tablet 76 Phenyramidol Hydrochloride Analgesic-muscle relaxant. August-1962 200mg Tablet 77 Paramethasone Acetate Corticosteroid. August-1962 78 Fluocinolone Acetonide Corticosteroid. August-1962 79 Nicotinamide Hydrochloride B complex. September-1962 80 Pyrvinium Pamoate Anthelmintic. October-1962 81 Lymecycline Antibiotic. October-1962 82 Trithiopara Methoxy Phenyl Oral formulation. October-1962 Propene 83 Trihexyphenidyl Hcl. November-1962 Sustained Release Tablet 84 Methylprednisolone Acetate Corticosteroid- for local & November-1962 40mg/ml Vial systemic administration. 85 Sodium Tolbutamide Injection Diagnostic. November-1962 86 Polio Virus Vaccine Live Prophylactic. November-1962 (Oral) Sabine strain type- I, II, III (0.1ml) 87 Tranylcypromine Sulphate Anti-depressant. December-1962 10mg Tablet 88 Bromo-Naphthol 250mg Tablet Anthelmintic - in hook warm February-1963 infection only. 89 Zinc Glucoheptonate Mineral supplement. February-1963 90 Methandienone 1mg/5mg Anabolic agent. February-1963 Tablet 91 Methyl Dopa 250mg Tablet Antihypertensive. March-1963 92 Iron Polymaltose (2ml=100mg Antianaemia-iron therapy. April-1963 Fe) Ampoule 93 Dehydro-Emetine Ampoule Anti-emetine (synthetic). April-1963 94 Oxacillin Sodium 250mg New synthetic penicillin-use in April-1963 Capsule Staph. resistance cases. 95 Streptokinase-Streptodornase Anti-inflammatory. April-1963 Oral Tablet 96 Chlorzoxazone 250mg Tablet Muscle relaxant. April-1963 97 Sodium Polyhydroxy Antacid. May-1963 Aluminium Monocarbonate Hexitol Complex (360mg) Tablet 98 Phenylbutazone Calcium Anti-inflammatory, anti- May-1963 200mg & 50mg Tablet rheumatic. 99 Thioproperazine 1/5/10/25mg Neuroleptic. June-1963 Tablet, 0.75% Ampoule 100 Tetrahydro furfuryl salicylate + Antirheumatic. July-1963 Ethyl nicotenate + n-Hexyl nicotinate - Ointment 101 Phenylbutazone Sodium August-1963 Parentral Form 102 Trifluoperazine & Antianxiety & depression. August-1963 Tranylcypromine 1mg/10mg Tablet 103 Chlorthalidone Diuretic. September-1963 104 Methoxyflurane (Bottle of Inhalation anaesthetic. October-1963 125ml) 105 Chlosal Butamide Antifungal. October-1963 Ointment/Solution/Dusting Powder 106 Metaraminol Bitartarate Sympathomimetic (adrenergic) January-1964 (10mg/ml) 1ml & 10ml Vial urgent vasopressor. 107 Oestradiol Phenyl Propionate Hormone. January-1964 1ml Ampoule 108 Dichlorphenamide 50mg Carbonic anhydrase inhibitor. January-1964 Tablet 109 Methotrimeprazine (acid January-1964 maleate) 5/25/100mg Tablet & 25mg/cc Ampoule 110 Lynestrenol Progesterone hormone. January-1964 112 Quinethazone 50mg Tablet Diuretic (oral). January-1964 113 Allyloestrenol 5mg Tablet Progestational compound. January-1964 114 Mebhydroline Napadisylate Antihistaminic. February-1964 50mg
Load more

Recommended publications
  • Anabolic Steroid Use Misuse and Addiction
    Anabolic Steroid Use, Misuse And Addiction JASSIN M. JOURIA Dr. Jassin M. Jouria is a medical doctor, professor of academic medicine, and medical author. He graduated from Ross University School of Medicine and has completed his clinical clerkship training in various teaching hospitals throughout New York, including King’s County Hospital Center and Brookdale Medical Center, among others. Dr. Jouria has passed all USMLE medical board exams, and has served as a test prep tutor and instructor for Kaplan. He has developed several medical courses and curricula for a variety of educational institutions. Dr. Jouria has also served on multiple levels in the academic field including faculty member and Department Chair. Dr. Jouria continues to serve as a Subject Matter Expert for several continuing education organizations covering multiple basic medical sciences. He has also developed several continuing medical education courses covering various topics in clinical medicine. Recently, Dr. Jouria has been contracted by the University of Miami/Jackson Memorial Hospital’s Department of Surgery to develop an e-module training series for trauma patient management. Dr. Jouria is currently authoring an academic textbook on Human Anatomy & Physiology. ABSTRACT The synthetic versions of the male hormone testosterone, also known as anabolic steroids, can play an important role in the treatment of health conditions when used as prescribed by a medical clinician. However, misuse of anabolic steroids occurs when these substances are used solely to improve physical appearance or performance. Because there are some potentially serious physical effects of anabolic steroid use, it is important that anabolic steroids are only used as prescribed and always under a medical clinician’s guidance.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • PRODUCT MONOGRAPH ORCIPRENALINE Orciprenaline Sulphate Syrup House Standard 2 Mg/Ml Β2-Adrenergic Stimulant Bronchodilator AA P
    PRODUCT MONOGRAPH ORCIPRENALINE Orciprenaline Sulphate Syrup House Standard 2 mg/mL 2-Adrenergic Stimulant Bronchodilator AA PHARMA INC. DATE OF PREPARATION: 1165 Creditstone Road, Unit #1 April 10, 2014 Vaughan, Ontario L4K 4N7 Control Number: 172362 1 PRODUCT MONOGRAPH ORCIPRENALINE Orciprenaline Sulfate Syrup House Standard 2 mg/mL THERAPEUTIC CLASSIFICATION 2–Adrenergic Stimulant Bronchodilator ACTIONS AND CLINICAL PHARMACOLOGY Orciprenaline sulphate is a bronchodilating agent. The bronchospasm associated with various pulmonary diseases - chronic bronchitis, pulmonary emphysema, bronchial asthma, silicosis, tuberculosis, sarcoidosis and carcinoma of the lung, has been successfully reversed by therapy with orciprenaline sulphate. Orciprenaline sulphate has the following major characteristics: 1) Pharmacologically, the action of orciprenaline sulphate is one of beta stimulation. Receptor sites in the bronchi and bronchioles are more sensitive to the drug than those in the heart and blood vessels, so that the ratio of bronchodilating to cardiovascular effects is favourable. Consequently, it is usually possible clinically to produce good bronchodilation at dosage levels which are unlikely to cause cardiovascular side effects. 2 2) The efficacy of the bronchodilator after both oral and inhalation administration has been demonstrated by pulmonary function studies (spirometry, and by measurement of airways resistance by body plethysmography). 3) Rapid onset of action follows administration of orciprenaline sulphate inhalants, and the effect is usually noted immediately. Following oral administration, the effect is usually noted within 30 minutes. 4) The peak effect of bronchodilator activity following orciprenaline sulphate generally occurs within 60 to 90 minutes, and this activity lasts for 3 to 6 hours. 5) Orciprenaline sulphate taken orally potentiates the action of a bronchodilator inhalant administered 90 minutes later, whereas no additive effect occurs when the drugs are given in reverse order.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Effects of Androgenic-Anabolic Steroids on Apolipoproteins and Lipoprotein (A) F Hartgens, G Rietjens, H a Keizer, H Kuipers, B H R Wolffenbuttel
    253 Br J Sports Med: first published as 10.1136/bjsm.2003.000199 on 21 May 2004. Downloaded from ORIGINAL ARTICLE Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a) F Hartgens, G Rietjens, H A Keizer, H Kuipers, B H R Wolffenbuttel ............................................................................................................................... Br J Sports Med 2004;38:253–259. doi: 10.1136/bjsm.2003.000199 Objectives: To investigate the effects of two different regimens of androgenic-anabolic steroid (AAS) administration on serum lipid and lipoproteins, and recovery of these variables after drug cessation, as indicators of the risk for cardiovascular disease in healthy male strength athletes. Methods: In a non-blinded study (study 1) serum lipoproteins and lipids were assessed in 19 subjects who self administered AASs for eight or 14 weeks, and in 16 non-using volunteers. In a randomised double blind, placebo controlled design, the effects of intramuscular administration of nandrolone decanoate (200 mg/week) for eight weeks on the same variables in 16 bodybuilders were studied (study 2). Fasting serum concentrations of total cholesterol, triglycerides, HDL-cholesterol (HDL-C), HDL2-cholesterol (HDL2- C), HDL3-cholesterol (HDL3-C), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), and lipoprotein (a) (Lp(a)) were determined. Results: In study 1 AAS administration led to decreases in serum concentrations of HDL-C (from 1.08 (0.30) to 0.43 (0.22) mmol/l), HDL2-C (from 0.21 (0.18) to 0.05 (0.03) mmol/l), HDL3-C (from 0.87 (0.24) to 0.40 (0.20) mmol/l, and Apo-A1 (from 1.41 (0.27) to 0.71 (0.34) g/l), whereas Apo-B increased from 0.96 (0.13) to 1.32 (0.28) g/l.
    [Show full text]
  • Metabolism of Anabolic Steroids in Man: Synthesis and Use of Reference Substances for Identification of Anabolic Steroid Metabolites
    Anaiytzca Chumca Acta, 275 (1993) 23-48 23 Elsevler hence Publishers B V , Amsterdam Metabolism of anabolic steroids in man: synthesis and use of reference substances for identification of anabolic steroid metabolites Will1 Schanxer and Manfred Domke LkutscheS’rthochschuk Koln, Inrhtut f?u Bwchemre, Carl-L&m-Weg 4 5ooO Cologne 41 (Germuny) (Recewed 20th May 1992) AhStl-& The use of anabohc steroids was banned by the International Olympic Comnuttee for the first tune at the Olympic Games m Montreal m 1976 Since that tie the nususe of anabohc steroxls by athletes has been controlled by analysis of urme extracts by gas chromatography-mass spectrometry @C-MS) The excreted steroids or their metabohtes, or both, are isolated from urme by XAD-2 adsorption, enzymatx hydrolyss of coqlugated excreted metabobtes anth /?-glucuromdase from Es&en&u co& bqmd-bqmd extractlon mth diethyl ether, and courted mto tnmethylsdyl (‘INiS) derwatwes The confirmation of an anabobc stenxd nususe ts based on comparison of the electron nnpact lomzation (EI) mass spectrum and GC retention tie of the isolated steroid and/or its metabohte with the El mass spectrum and GC retention time of authentic reference substances For this purpose excretion studies with the most common anabobc steroids were performed and the mam excreted metabobtes were synthesued for bolasterone, boldenone, 4-chiorodehydromethyltestosterone, clostebol, drostanolone, tluoxymesterone, forme- bolone, me&a&one, mesterolone, metandlenone, methandnol, metenolone, methyltestosterone, nandrolone, norethandrolone,
    [Show full text]
  • Treatment for Calcium Channel Blocker Poisoning a Systematic Review
    Clinical Toxicology ISSN: 1556-3650 (Print) 1556-9519 (Online) Journal homepage: http://www.tandfonline.com/loi/ictx20 Treatment for calcium channel blocker poisoning: A systematic review M. St-Onge, P.-A. Dubé, S. Gosselin, C. Guimont, J. Godwin, P. M. Archambault, J.-M. Chauny, A. J. Frenette, M. Darveau, N. Le sage, J. Poitras, J. Provencher, D. N. Juurlink & R. Blais To cite this article: M. St-Onge, P.-A. Dubé, S. Gosselin, C. Guimont, J. Godwin, P. M. Archambault, J.-M. Chauny, A. J. Frenette, M. Darveau, N. Le sage, J. Poitras, J. Provencher, D. N. Juurlink & R. Blais (2014) Treatment for calcium channel blocker poisoning: A systematic review, Clinical Toxicology, 52:9, 926-944, DOI: 10.3109/15563650.2014.965827 To link to this article: http://dx.doi.org/10.3109/15563650.2014.965827 © 2014 The Author(s). Published by Taylor & View supplementary material Francis. Published online: 06 Oct 2014. Submit your article to this journal Article views: 8320 View related articles View Crossmark data Citing articles: 47 View citing articles Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ictx20 Download by: [Bird Lib Ouhsc] Date: 14 November 2017, At: 06:23 Clinical Toxicology (2014), 52, 926–944 Copyright © 2014 Informa Healthcare USA, Inc. ISSN: 1556-3650 print / 1556-9519 online DOI: 10.3109/15563650.2014.965827 REVIEW ARTICLE Treatment for calcium channel blocker poisoning: A systematic review M. ST-ONGE,1,2,3 P.-A. DUBÉ,4,5,6 S. GOSSELIN,7,8,9 C. GUIMONT,10 J.
    [Show full text]
  • Intracavernous Methoxamine in the Treatment of Priapism
    International Journal of Impotence Research (1998) 10, 257±259 ß 1998 Stockton Press All rights reserved 0955-9930/98 $12.00 http://www.stockton-press.co.uk/ijir Case Report Intracavernous methoxamine in the treatment of priapism J Jara, I Moncada, G Bueno and C Hernandez Urology Department, Hospital General Universitario, Madrid, Spain Methoxamine is an alpha-adrenergic drug, its unique pharmacokinetics and mechanism of action on alpha-1 receptors lead to consider it, similarly to phenylephrine, as a ®rst-choice drug for treating drug-induced or veno-occlusive priapism. The experience obtained with its use in the management of three cases of priapism lasting over 7 h and one case of sustained rigid erection caused during anesthetic induction are reported. Keywords: methoxamine; priapism; intracavernous drug therapy Introduction adrenergic agents. In a later phase, cell ischemia and ®brosis takes place, making the smooth muscle irresponsive to pharmacologic agents. Since the introduction of intracavernous injections In this present study we report on the ef®cacy and of vasoactive drugs in clinical practice, the inci- safety of methoxamine, a selective alpha-1 adrener- dence of priapism have enormously increased, from gic agent, in the treatment of drug-induced pri- 1 being an occasional ®nding to be the most common apism. cause of priapism, according to Lue.2 The incidence of this untoward effect of intra- cavernous injections depends on the drug used, the dose administered and the underlying etiology of Case reports impotence. In a review of the literature,3 papaverine induced priapism in 9.5% of 2314 patients, the Case 1 combination of papaverine plus phentolamine in 5.3% of 2914 patients and PGE1 only in 2.4% of the A 44 y old male presented to the urology department 1284 patients revised.
    [Show full text]
  • Megestrol Acetate/Melengestrol Acetate 2115 Adverse Effects and Precautions Megestrol Acetate Is Also Used in the Treatment of Ano- 16
    Megestrol Acetate/Melengestrol Acetate 2115 Adverse Effects and Precautions Megestrol acetate is also used in the treatment of ano- 16. Mwamburi DM, et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar As for progestogens in general (see Progesterone, rexia and cachexia (see below) in patients with cancer results in 2 months. Clin Infect Dis 2004; 38: 895–902. p.2125). The weight gain that may occur with meges- or AIDS. The usual dose is 400 to 800 mg daily, as tab- 17. Grunfeld C, et al. Oxandrolone in the treatment of HIV-associ- ated weight loss in men: a randomized, double-blind, placebo- trol acetate appears to be associated with an increased lets or oral suspension. A suspension of megestrol ace- controlled study. J Acquir Immune Defic Syndr 2006; 41: appetite and food intake rather than with fluid reten- tate that has an increased bioavailability is also availa- 304–14. tion. Megestrol acetate may have glucocorticoid ef- ble (Megace ES; Par Pharmaceutical, USA) and is Hot flushes. Megestrol has been used to treat hot flushes in fects when given long term. given in a dose of 625 mg in 5 mL daily for anorexia, women with breast cancer (to avoid the potentially tumour-stim- cachexia, or unexplained significant weight loss in pa- ulating effects of an oestrogen—see Malignant Neoplasms, un- Effects on carbohydrate metabolism. Megestrol therapy der Precautions of HRT, p.2075), as well as in men with hot 1-3 4 tients with AIDS. has been associated with hyperglycaemia or diabetes mellitus flushes after orchidectomy or anti-androgen therapy for prostate in AIDS patients being treated for cachexia.
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children with Cancer
    This is a repository copy of Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-induced Nausea and Vomiting in Children with Cancer. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/97043/ Version: Accepted Version Article: Flank, Jaqueline, Robinson, Paula, Holdsworth, Mark et al. (7 more authors) (2016) Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-induced Nausea and Vomiting in Children with Cancer. Pediatric blood & cancer. ISSN 1545-5009 https://doi.org/10.1002/pbc.25955 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Pediatric Blood & Cancer Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-induced Nausea and Vomiting in Children with Cancer Journal: Pediatric Blood & Cancer Manuscript ID PBC-15-1233.R1 Wiley - ManuscriptFor
    [Show full text]